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Abstract
Electroporation (EP) is a simple in vivo method to deliver normally impermeable molecules, such
as plasmid DNA, to a variety of tissues. Delivery of plasmid DNA by EP to a large surface area is
not practical because the distance between the electrode pairs, and therefore the applied voltage,
must be increased to effectively permeabilize the cell membrane. The design of the MultiElectrode
Array (MEA) incorporates multiple electrode pairs at a fixed distance to allow for delivery of
plasmid DNA to the skin potentially reducing the sensation associated with in vivo
electroporation. In this report, we evaluate the effects of field strength and pulse width on
transgene expression and duration using a plasmid encoding the luciferase reporter gene delivered
by intradermal injection in a guinea pig model followed by EP with the MEA. As expected, the
level of luciferase expression increased with the magnitude and duration of the voltage applied. In
addition to adjusting transgene expression levels by altering fielding strength, levels could also be
controlled by adjusting the plasmid dose. Our results indicate that the design of the MEA is a
viable option for cutaneous plasmid DNA delivery by in vivo EP to a large surface area.
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Introduction
Direct injection of plasmid DNA has been intensely investigated as a gene delivery approach
for the treatment of a variety of diseases. One drawback to this approach is inefficient
uptake of the plasmid DNA by cells, which results in low levels of gene expression 1. In
vivo EP utilizes the application of a controlled pulsed external electric field that slightly
surpasses the capacitance of the cell membrane to transiently increase cell membrane
permeability and allow for an increase in the uptake of plasmid DNA by the cell.
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The use of an electrical field to increase plasmid uptake and expression (in vivo
electroporation or electrotransfer) is more efficient when the electric field is applied in more
than one direction 2–5. This approach permeabilizes a greater area of the cell surface and a
larger number of cells in the target tissue 4. Prior to the development of the four plate
electrode (4PE) 5–7, electrotransfer of plasmid DNA to skin was typically facilitated with a
two-plate caliper electrode. One drawback to this approach is the requirement of the
electrode plates to be manipulated around the treatment site to administer multiple sets of
pulses in different orientations. Removal and replacement of the caliper electrode from the
delivery site resulted in variation in the distance between the electrode plates and thus
variation in the applied voltage. The design of the multielectrode array (MEA) 8, 9 expands
on the configuration of the 4PE. The MEA is composed of an array of 16 small blunt
electrodes in a 4 by 4 configuration with a 2-mm gap width between electrodes. Similar to
the 4PE, the design of the MEA allows for multiple sets of electric pulses to be applied in
two electric field orientations at a 90° angle without removing the electrode from the skin.
Another drawback to other electrode designs is that to deliver plasmid to a large surface area
the gap between the electrode pairs must be increased, and thus, the applied voltage must
also be increased for cell permeabilization to be effective. The configuration of the MEA
allows for its dimensions to be easily expanded, enabling a larger surface area to be treated
without the need to increase the distance between electrodes. This larger treatment area may
be necessary for some cutaneous indications, such as dermatological disorders. In addition,
if higher transgene expression is necessary for a particular condition, treatment of a larger
tissue area may result in proportionally increased expression.
In our initial report describing the MEA we compared reporter gene expression after
delivering plasmid DNA with the 4PE and MEA in different rodent models 8. While rodent
models are often used in the design of delivery protocols, guinea pig skin is of similar
thickness and vascularity to human skin and is well established as a suitable model for
human skin for drug delivery and toxicity studies 10–12. The focus of the work presented
here was to further evaluate and optimize the delivery parameters for the MEA in the guinea
pig model. This refinement of the MEA delivery conditions will facilitate the translation of
this delivery method to clinical trials. Specifically, we evaluated the effects of varying field
strength and pulse width on transgene expression, examined the duration of transgene
expression, evaluated if there is a dose response relationship between amount of plasmid
delivered and resulting expression levels and determined if expression could be increased by
expanding the treatment area.
Results
Effect of field strength and pulse width on transgene expression
Previous work determined delivery of pLuc at field strength of 300 V/cm and 150 ms pulse
width applied with the MEA resulted in the highest and most reproducible luciferase protein
expression 8. To evaluate the effects of field strength and pulse width for plasmid delivery
with the MEA in this cutaneous model, three field strengths (300 V/cm, 250 V/cm and 225
V/cm) were examined with varying pulse widths, ranging from 50 ms to 350 ms (Figure 1).
In these initial experiments, luciferase expression was evaluated utilizing an in vitro assay.
To minimize the number of animals used, expression was analyzed 48 hours after delivery.
In previous work, high expression was observed at this time point5,8. Additional time points
were evaluated when utilizing in vivo analysis as described below in kinetics or expression
section. Two days after pLuc delivery, the delivery sites were excised and luciferase activity
determined by a standard in vitro luciferase assay. For all three field strengths and pulse
widths with exception of 250 V/cm with 50 ms pulses, a significant increase in luciferase
expression compared to injection of plasmid injection without EP was observed (p< 0.001).
In general, a pulse duration of longer than 150 ms resulted in slightly higher levels of
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luciferase expression, but 150 ms provided the highest level of expression with the least
variation and minimal visual damage to the delivery area. Damage was assessed based on
the presence of redness, burning and/or thickening of the skin immediately following and
during the first 48 hours after administration of electric pulses. None of the delivery
conditions used here resulted in burning, but 300 V/cm did result in increased redness
starting immediately after application of pulses and thickening of the skin at the time the
tissue was sampled (48 hours).
Kinetics of expression
The results presented in Figure 1 utilized in vitro luciferase assays to evaluate transgene
expression. The luciferase expression in subsequent figures was determined by in vivo
bioluminescence imaging, which allowed for the use of fewer experimental animals and to
have the same treatment site followed over time. The in vitro and in vivo assays highly
correlated in a small study (r2= 0.94, n=8) and thus the in vivo assay was used for the
remainder of this study.
Because a pulse width of 150 ms for each of the field strengths examined (300 V/cm, 250 V/
cm and 225 V/cm) consistently resulted in the highest level of transgene expression, we next
determined the duration of transgene expression after pLuc delivery at 300 V/cm, 250 V/cm
and 225 V/cm with 150 ms pulses. A significant increase in luciferase expression was
observed at all three field strengths at 24 hours after delivery (Figure 2). For delivery at both
300 V/cm and 250 V/cm, luciferase expression remained significantly higher through day 17
(p< 0.001) and decreased to non-significance 21 days after delivery (data not shown). At
225 V/cm, luciferase expression remained significantly higher through day 10 (p < 0.001),
lost significance on day 14 (p=0.103), but increased at day 17 (p< 0.001) before returning to
background levels on day 21 (data not shown). Luciferase expression for all field strengths
did not significantly decrease from the initial peak at 24 hours until day 10 (p<0.001). In
contrast, luciferase expression after pLuc injection without pulse application was
significantly lower by 96 hours after delivery than the initial peak at 24 hours (p<0.001).
Delivery using 300 V/cm 150 ms pulses resulted in slightly higher expression. However,
some visible damage to the treated area was observed, although the damage level was lower
than what was observed previously with longer pulse widths. Therefore, since 250 V/cm 150
ms pulses resulted in high expression levels and no visible skin damage, these EP conditions
were used for the remaining experiments.
Dose response
To examine the relationship between plasmid dose and the resulting luciferase expression
we delivered 20 μg, 50 μg, 100 μg, 150 μg and 200 μg of pLuc at 250 V/cm and 150 ms
pulses (Figure 3, top panel). Two days after delivery, luciferase expression was determined
using in vivo bioluminescence imaging (Caliper Life Sciences, Hopkinton, MA).
Statistically discernable differences in expression were noted between 20, 100, and 200 μg
(p<0.01). Since the plasmid concentration was maintained, each increased dosage required
an increased injection volume. This increase in volume did not significantly affect transgene
expression (Figure 3, bottom panel).
3.4 Expanded treatment area
The MEA is designed to be easily expanded by the addition of electrode rows while
maintaining the same distance between electrodes. This allows delivery to a larger area
without an increase in the applied voltage. To test this concept, larger injection areas with
and without pulse delivery were evaluated. Three types of injections at a concentration of 2
μg/μl pLuc were utilized: a single 50 μl injection (100 μg); a single 200 μl injection (400
μg); and four 50 μl injections (400 μg) adjacent to each other forming approximately a
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12×12 mm area. Several pulse protocols were tested (Figure 4). For the single injections,
pulses were applied in a single 6×6 mm area application directly to the injection area. Four
individual pulse applications were applied in a 12×12 mm area containing a single 200 μl
injection or four 50 μl injections. Two days after delivery, luciferase expression was
determined by in vivo bioluminescence imaging. Delivery of pLuc (100 μg or 400μg dose)
with electroporation (single or four pulse applications) resulted in significantly increased
(p<0.05) expression. When compared to a single injection of 100 μg pLuc followed by a
single pulse application, luciferase expression following delivery of 400 μg pLuc was
significantly increased with a single injection with four pulse applications (p<0.05), or with
four injections followed by four pulse applications (p<0.05). The increase in expression
between 100 and 400 μg, no matter the pulsing protocol, was approximately 4–7 fold. These
results provide evidence that the expansion of the MEA could enhance expression levels.
Discussion
The first reports of successful delivery of plasmid DNA with electrotransfer were conducted
in rat liver 13, mouse brain tumors 14, and mouse skeletal muscle 15. Since these initial
experiments, this technique has also been used for plasmid delivery to a wide variety of
tissues 16, 17 including skin 18. Plasmid electrotransfer to the skin has been performed in
several preclinical models producing both systemic and tissue-specific expression 5–9, 19–38.
This approach has shown promise in several fields including vaccines for infectious
disease20, 23, 25, 27, 30, 33, 34 and cancer 26, 36, wound healing 7, 24, 31, and protein
replacement 38. Cutaneous gene therapy could potentially be used to treat a variety of
diseases. The skin is an attractive target because it is easily accessible. For example,
systemic transgene expression levels can potentially be controlled by controlling the
treatment area or the number of treatments.
The electrodes used for skin delivery range from penetrating or needle electrodes 19, 20, 24,
26, 30, 31, 33, 36, 37, 39 to electrodes placed on the skin surface 5–9, 20–23, 25, 28, 29, 32, 35, 38.
Several descriptions of the fabrication of microneedle electrodes have been published; two
have been tested in vivo for plasmid delivery 27, 39. Delivery with the MEA differs in that
the blunt electrodes in the array do not penetrate the skin.
As mentioned previously, electrotransfer with the MEA at 300 V/cm 150 ms pulses resulted
in high, reproducible luciferase protein expression in rodent models 8. In those previous
studies, equivalent expression could be obtained with the 4PE using 100 V/cm 150 ms
pulses. Although it was necessary to increase the field strength (applied voltage remained
the same) to achieve comparable expression patterns with the MEA, muscle stimulation
during pulse administration was greatly reduced or eliminated when compared to the
pronounced muscle contractions seen with the 4PE and caliper electrodes. It was necessary
to increase the field strength due to the shorter distance between the electrodes which would
decrease the depth of electric field penetration. This could also explain the decreased nerve
stimulation and muscle twitching. The lack of a significant increase in luciferase expression
with 50 ms pulses delivered at 250 V/cm (Figure 1) indicates that within the pulse widths
tested, 100 ms may be the minimum pulse duration required to reach the necessary level of
cell membrane permeabilization for increased plasmid uptake at a field strength of 250 V/cm
or less. In the guinea pig model, delivery of pLuc at 300 V/cm resulted in similar luciferase
expression at all pulse widths examined when compared to lower field strength pulses
(Figure 1), but tissue damage after delivery was frequently observed. The visually detectable
damage may be the underlying cause of the increased variability in luciferase expression
with this field strength. Compared to 225 V/cm, luciferase expression was consistently
higher with 250 V/cm at comparable pulse widths.
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It was previously reported that transgene expression decreases 3 days after plasmid DNA
delivery by intradermal injection 40. Consistent with these findings, in this study luciferase
expression after plasmid injection without pulses significantly decreased between days 3 and
4 after delivery compared to the initial peak expression at 24 hours (Figure 2). For all
electrotransfer conditions tested, a significant decrease in luciferase expression occurred 10
days after delivery when compared to the initial peak at 24 hours. Expression after delivery
with 300 V/cm and 250 V/cm remained greater than injection alone for 17 days. This
decrease in expression is probably due to the limited lifespan of the skin cell. Longer
expression would indicate delivery to the underlying panniculus carnosus muscle 29, 36. The
significant difference in expression with 225 V/cm at day 17 (Figure 2) is most likely due to
the decrease in luciferase expression in the plasmid injection alone group. In addition, the
group receiving 225 V/cm pulses produced lower overall luciferase expression than the
higher field strength groups beginning with day 10 after delivery. These results indicate that
if a lower level of expression is desired, it could be achieved by decreasing the field
strength.
Since a linear correlation between the plasmid dosage and the resulting transgene expression
(r2=0.88) was observed up to the highest plasmid dose tested (Figure 3a), the maximum
expression levels were not reached. Further experiments will be needed to determine the
dose required to achieve the maximum level of expression.
The MEA is designed to be expandable to cover a larger surface area to increase transgene
expression. This concept was evaluated by performing the delivery to an area approximately
four times the original size. Electrotransfer over a 12×12 mm area following a single 200 μg
injection or four 50 μg injections significantly increased expression when compared to
electrotransfer after a single 50 μg injection. This supports the concept that expansion of the
MEA to cover a larger surface area would enhance expression.
In summary, the level of luciferase expression increased with the magnitude of the voltage
applied. For each of the field strengths examined, a pulse duration of 150 ms achieved the
highest level of expression with the least variation and visible tissue damage. For all three
field strengths examined, luciferase expression did not decrease from initial peak expression
at 24 hours until 10 days (225 V/cm) to 17 (300 V/cm and 250 V/cm) days after delivery. In
addition to adjusting transgene expression levels by altering field strengths, expression
levels can also be controlled by adjusting the plasmid dose or the skin area treated. These
results indicated that the design of the MEA is a viable option for delivery of plasmid DNA
to a larger area of skin without the need to increase the voltage applied and could potentially




All procedures were approved by the Animal Use and Care Committee of the University of
South Florida College of Medicine. Delivery was performed to female 175–200 gram
Hartley guinea pigs (Elm Hill Laboratories, Chelmsford, MA or Charles River Laboratories,
Wilmington, MA). During plasmid delivery and in vivo quantification of luciferase
expression animals were anesthetized in an induction chamber charged with 3% isoflurane
in O2 then fitted with a standard rodent mask and kept under general anesthesia during the
procedure.
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The luciferase plasmid gWizLuc (pLuc) was commercially prepared (Aldevron, Fargo, ND).
Endotoxin levels were <0.1 EU/μg plasmid. Electrotransfer was carried out as previously
described 8. Briefly, 50 μl gWizLuc in sterile injectable saline (2 μg/μl) was injected
intradermally on the guinea pig flank at four sites using a 25 gauge, 5/8-inch length needle.
The MEA was then placed over the injection bubble and an electrical field applied at the
indicated field strength and pulse width. Multiple conditions were tested on each animal, and
on site on each animal was an injection-only control. For sites receiving electric pulses, 72
pulses were applied over the 16 electrodes, resulting in approximately 8 pulses per 2×2
section. Delivery sites were marked with a surgical marker if they were to be excised later
for quantification of luciferase expression.
In Vitro Luciferase Assays
Luciferase activity was quantified as previously described 41. Briefly, at the indicated time
points animals were humanely euthanized and delivery sites were excised and snap frozen
on dry ice. Tissue samples were homogenized in 1 to 2 mL of homogenization buffer (25
mM Tris, pH 7.8, 2 mM EDTA, 1 mM DTT and 10% glycerol). Homogenates were
centrifuged at 4°C for 2 minutes and the supernatants were removed and assayed for
luciferase activity in Luciferase Assay Buffer (25 mM glycylglycine, pH 7.8, 15 mM KPO4,
pH 7.8, 15 mM MgSO4, 4 mM EGTA, 2 mM ATP, 1 mM DTT and 100 μM Luciferin).
Luciferase activity was quantitated using a MLX microtiter plate luminometer (Dynex
Technologies, Chantilly, VA). Using a standard preparation of recombinant luciferase
(Promega, Madison, WI) relative light unit values were converted to pg of luciferase and
luciferase activity is reported as total pg luciferase per tissue sample.
In Vivo Bioluminescence Imaging
In vivo bioluminescence imaging was performed using the IVIS Spectrum system (Caliper
Life Sciences, Hopkinton, MA) in conjunction with the Living Image acquisition and
analysis software. Luciferin (Caliper Life Sciences) was dissolved to 7.5 mg/ml in PBS,
filter-sterilized, and stored at −20°C. Guinea pigs were anesthetized with isofluorane and
received a 50 μL intradermal injection of the luciferin solution at the delivery site. Images
were acquired 2 minutes after luciferin injection. Quantitation of luciferase activity was
based on total flux (photons/sec) of emitted light from the selected area around the delivery
site 42
Statistical Analysis
All values are reported as the mean ± SEM unless otherwise noted. Analysis of luciferase
activity was completed using a 2-tailed Student’s t-test when comparing two groups.
Analysis three or more groups was completed by ANOVA with a post-hoc Fisher’s Least
Significant Difference test to adjust for multiple comparisons. Statistical significance was
assumed at p< 0.05. All statistical analysis was completed using the Statistical Package for
the Social Sciences (SPSS).
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Figure 1. Effect of field strength and pulse width luciferase expression
Luciferase expression was determined 48 hours after delivery using an in vitro assay for the
indicated field strengths (V/cm) and pulse widths (ms). * p< 0.001 compared to plasmid
injection alone (pLucE−).
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Figure 2. Luciferase expression kinetics
Luciferase expression was determined at the indicated time points using an in vivo assay for
the indicated field strengths (V/cm) with 150 ms pulse widths. pLucE− and 225 V/cm, n=16
per group per time point; 250 V/cm, n=15 per group per time point; 300 V/cm, n=14 per
group per time point. *p< 0.001 compared to pLucE− for that time point.
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Figure 3. Control of luciferase expression by plasmid dose
Luciferase expression was determined 48 hours after pLuc delivery using an in vivo assay.
pLucE+ = 250 V/cm 150 ms.
Top panel. For 20 μg, 150 μg and 200 μg, n=6 per group for both pLucE− and pLucE+; 100
μg, n=8 per group for both pLucE− and pLucE+; 50 μg pLucE−, n=6; 50 μg pLucE+, n=5.
*p< 0.05 for that plasmid dose, ‡ p< 0.05 compared to expression with pLucE+ delivering
100 μg. Bottom panel. Luciferase expression was determined for 100 μg pLuc in the
indicated injection volume. n=8 per group. *p< 0.001 compared to pLucE− for that injection
volume.
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Figure 4. Expansion of treated area
Luciferase expression was determined 48 hours after pLuc delivery using an in vivo assay.
Pulses were applied at a field strength of 250 V/cm and a pulse length of 150 ms. 1EP =
placing the MEA over the center of the injection area and applying one application of
pulses; 4EP = placing the MEA over each of 4 quadrants and applying one application of
pulses at each site for a single 400 μg injection or placing the MEA over each of 4 injection
sites and applying application of pulses at each site for the four 100 μg injections. % =
p<0.02 compared to four 100 μg injections without pulse application; # = p<0.02 compared
to 400 μg injection; $ = p<0.05 compared to one injection of 100 μg with application of
pulses; and * = p<0.05 compared to one 100 μg without pulse application.
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